SUNPHARMA Stock Overview
A generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sun Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,699.80 |
| 52 Week High | ₹1,960.35 |
| 52 Week Low | ₹1,377.20 |
| Beta | 0.39 |
| 1 Month Change | -5.85% |
| 3 Month Change | 6.69% |
| 1 Year Change | 16.50% |
| 3 Year Change | 97.75% |
| 5 Year Change | 243.50% |
| Change since IPO | 83,514.62% |
Recent News & Updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
May 25
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching
May 15Recent updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
May 25Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching
May 15Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Shares May Have Run Too Fast Too Soon
Feb 23Analysts Are Updating Their Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Estimates After Its Third-Quarter Results
Feb 05Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 04Here's Why Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Caught The Eye Of Investors
Jan 29Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges
U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Shareholder Returns
| SUNPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.1% | -0.4% | 0.5% |
| 1Y | 16.5% | 13.1% | 3.7% |
Return vs Industry: SUNPHARMA exceeded the Indian Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: SUNPHARMA exceeded the Indian Market which returned 3.7% over the past year.
Price Volatility
| SUNPHARMA volatility | |
|---|---|
| SUNPHARMA Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.6% |
Stable Share Price: SUNPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SUNPHARMA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 43,000 | Dilip Shanghvi | www.sunpharma.com |
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs.
Sun Pharmaceutical Industries Limited Fundamentals Summary
| SUNPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹4.00t |
| Earnings (TTM) | ₹109.29b |
| Revenue (TTM) | ₹525.78b |
Is SUNPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUNPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹525.78b |
| Cost of Revenue | ₹107.47b |
| Gross Profit | ₹418.31b |
| Other Expenses | ₹309.02b |
| Earnings | ₹109.29b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 45.55 |
| Gross Margin | 79.56% |
| Net Profit Margin | 20.79% |
| Debt/Equity Ratio | 2.6% |
How did SUNPHARMA perform over the long term?
See historical performance and comparisonDividends
Does SUNPHARMA pay a reliable dividends?
See SUNPHARMA dividend history and benchmarks| Sun Pharmaceutical Industries dividend dates | |
|---|---|
| Ex Dividend Date | Jul 07 2025 |
| Dividend Pay Date | Aug 08 2025 |
| Days until Ex dividend | 38 days |
| Days until Dividend pay date | 70 days |
Does SUNPHARMA pay a reliable dividends?
See SUNPHARMA dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 11:23 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sun Pharmaceutical Industries Limited is covered by 74 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |